Edison system for Histotripsy
A groundbreaking technology for treating liver tumours.
Histotripsy
Histotripsy is a revolutionary new therapy for treating soft-tissue tumours. It an entirely non-invasive treatment method, without using scalpel or incisions. The treatment is based on precisely targeted high-intensity sound waves, which penetrate the patient’s body and focus exclusively on the diseased tumour tissue.
This method exploits the phenomenon of cavitation: in the treatment area, ultrasound forms microscopic bubbles, which implode in a fraction of a second, resulting in mechanical destruction of the diseased tissue at the sub-cellular level. At the same time, histotripsy minimally impacts the surrounding structures, such as blood vessels, nerve fibres and bile ducts. The harmless remnants from total destruction of the diseased tissue is naturally absorbed by the organism over the course of one to two months, without the need for surgical removal and without leaving scars.
In 2023 the histotripsy was approved by the US Food and Drug Administration for treatment of liver tumours, in July 2026 Edison received CE certification. In May 2026, HistoSonics submitted an application to FDA to expand the system’s therapeutic indications to include the treatment of kidney tumors.
The technology also has potential applications for the treatment of tumours of pancreas (clinical trials are currently underway for this indication), and in the future also for prostate and breast tumours and sarcomas.
Edison
The Edison system employs advanced imaging technologies, including an integrated USG system, as well as a robotic control system, to ensure highly precise treatment. This enables safely avoiding critical anatomic structures and protects healthy tissue. The treatment is conducted under general anaesthesia, solely for the purpose of completely immobilizing the patient. Along with the accompanying activities, the treatment lasts up to about three hours, while the actual removal of the tumour takes from several to several dozen minutes, depending on the size of the tumour.
It is possible to destroy several tumours in a single session. In most cases the therapy is limited to a single treatment. It is typically a one-day procedure, and the patient can return home the same day or the next day, most often without significant side effects such as pain.
Distribution and maintenance
Based on the agreement with the manufacturer Synektik has become an exclusive distributor of the Edison system in Poland, the Czech Republic, Slovakia, Lithuania, Latvia and Estonia.
Synektik is responsible for the sale of the systems and their servicing, as well as training, maintenance and accessories supply.
HistoSonics
HistoSonics is a medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumours.
The company is currently focused on commercializing their Edison system in the US and select global markets for liver treatment, while expanding histotripsy applications into other organs such as kidney, pancreas, prostate, and others.
